Sidley represented ADARx Pharmaceuticals, Inc. on the deal. ADARx Pharmaceuticals, Inc., a clinical-stage biotechnology company developing RNA-targeting therapeutics, announced its US$46 million Series B-1 financing. The proceeds...
Sidley represented ADARx Pharmaceuticals, Inc. on the deal. ADARx Pharmaceuticals, Inc., a clinical-stage biotechnology company developing RNA-targeting therapeutics, announced its US$46 million Series B-1 financing. The proceeds...